News

Long-Term Results of ASCT in Adult High-Risk Acute Lymphoblastic Leukemia

09/13/2022

Matched sibling and unrelated donor-based allogeneic hematopoietic stem cell transplantations in patients with BCR-ABL-negative acute lymphoblastic leukemia yielded similar long-term outcomes.

Matched sibling and unrelated...

09/13/2022

Oncology

News

Entinostat Plus Clofarabine Demonstrates Promising Safety, Efficacy for Philadelphia Chromosome-Negative ALL

06/18/2022

John Otrompke , BA, JD;

The histone deacetylase inhibitor entinostat plus clofarabine is active and tolerable in older, newly-diagnosed patients with Philadelphia chromosome-negative ALL and ABL.

The histone deacetylase...

06/18/2022

Oncology

News

Inotuzumab Ozogamicin Increases Time to Subsequent Salvage Therapy in ALL: INO-VATE Trial

06/15/2022

John Otrompke , BA, JD;

Inotuzumab ozogamicin is associated with longer time to first subsequent salvage therapy than standard chemotherapy for relapsed/refractory ALL, according to findings from the phase 3 INO-VATE trial.

Inotuzumab ozogamicin is...

06/15/2022

Oncology

News

Four Doses of Rituximab Plus Induction Therapy Does Not Improve EFS in Patients With ALL

05/31/2022

John Otrompke , BA, JD;

Four doses of rituximab plus standard induction therapy did not significantly improve EFS over standard of care induction alone for patients with de-novo ALL.

Four doses of rituximab plus...

05/31/2022

Oncology

News

Lower Tumor Burden Correlates to Better Response Rates Among Patients With ALL Receiving CAR-T Therapy

03/30/2022

John Otrompke , BA, JD;

Among patients with relapsed/refractory B-cell ALL receiving CAR-T therapy, the complete response rate was higher among those with lower tumor burden vs those with higher tumor burden, according to a recent study.

Among patients with ...

03/30/2022

Oncology

News

Stem Cell Transplant Plus CAR-T Improves Leukemia-Free Survival in Young Patients With ALL

03/10/2022

John Otrompke , BA, JD;

Study findings reveal hematopoietic stem cell transplant (HSCT) in young patients with ALL who had experienced CAR T-cell-induced remission, followed by functional persistence of remission for 63 days or less, significantly improved...

Study findings reveal...

03/10/2022

Oncology

News

CAR-T Therapy Shows Efficacy at Eliminating Residual Disease in B-ALL

03/10/2022

John Otrompke , BA, JD;

In a small clinical trial where patients with B-ALL with MRD were treated with CD19 CAR T-cell therapy, 85.7% responded, converting to MRD-negativity.

In a small clinical trial where...

03/10/2022

Oncology

News

Dual CAR-T Therapy Associated With High Remission in R/R B-Cell ALL

03/09/2022

John Otrompke , BA, JD;

Tandem CD19 and CD22 dual target CAR-T cells have been developed to achieve a CR in patients with R/R B-ALL.

Tandem CD19 and CD22 dual target...

03/09/2022

Oncology

News

CAR-T Therapy Brexucabtagene Autoleucel is a Treatment Option in R/R B-ALL

03/02/2022

CAR-T-cell therapy brexucabtagene autoleucel may offer a treatment option for patients with R/R B-ALL, according to results from the phase 2 ZUMA-3 trial.

CAR-T-cell therapy...

03/02/2022

Oncology

News

Tisagenlecleucel Gives Rise to an Immunogenic Response, but it Does not Affect Activity in ALL

03/02/2022

Immunogenic responses to the murine single-chain variable fragment domain contained in tisagenlecleucel did not affect the CAR-T therapy’s activity in young patients with R/R B-ALL and adult patients with R/R DLBCL.

Immunogenic responses to the...

03/02/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology